IL10 is a powerful TH-2 cell cytokine produced by lymphoid cells that limits HIV-1 replication in vivo, ostensibly by inhibiting macrophage͞monocyte and T-cell lymphocyte replication and secretion of inflammatory cytokines (IL1, TNF␣, IL6, IL8, and IL12). A genetic epidemiological scan of patients enrolled in AIDS cohorts for candidate gene-linked short tandem repeat polymorphisms revealed significant genotype associations for HIV-1 infection and progression to AIDS with markers adjacent to and tracking (by linkage disequilibrium) common single nucleotide polymorphic variants in the IL10 promoter region. Individuals carrying the IL10-5؊592A (IL10-5A) promoter allele possibly were at increased risk for HIV-1 infection, and once infected they progressed to AIDS more rapidly than homozygotes for the alternative IL10-5؊592 C͞C (IL10-؉͞؉) genotype, particularly in the later stages of HIV-1 infection. An estimated 25-30% of long-term nonprogressors (who avoid clinical AIDS for 10 or more years after HIV-1 infection) can be attributed to their IL10-؉͞؉ promoter genotype. Alternative IL10 promoter alleles are functionally distinct in relative IL10 production, in retention of an avian erythroblastosis virus transcription factor recognition sequence and in binding to specific putative nuclear transcription factors, suggesting a potential mechanism whereby IL10-5A down-regulation of inhibitory IL10 facilitates HIV-1 replication in vivo, accelerating the onset of AIDS.
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IL10 promoter variant (IL10-5ЈA)
A llelic variants in the human genome are likely to regulate susceptibility or resistance to HIV-1 infection and disease progression (1) (2) (3) . A hope to resolve the etiology of HIV-1 infection and the mechanisms of disease outcome has prompted a search for genetic variants in gene candidates thought to play a role in HIV-1 disease. Genetic epidemiologic analysis of AIDS cohorts has to date implicated at least eight human loci whose alleles exert differential influence on HIV infection and͞or AIDS pathogenesis among infected individuals: chemokine (c-c) receptor (CCR)5-⌬32, CCR5-P1, CCR2-64I, stromal cell-derived factor (SDF )1-3ЈA, mannose-binding lectin (MBL), and HLA-A, -B, and -C (4-13).
To detect additional genetic effects of polymorphic variants in genes whose products have been implicated in HIV-1 infection and AIDS progression, we identified 17 candidate loci with 19 closely linked short tandem repeat (STR) polymorphisms (also called microsatellites) ( Table 1) . Distortions in allele frequency, genotype frequency, and Hardy-Weinberg equilibrium (the tendency for genotype frequencies to occur according to a polynomial distribution) among clinical subdivisions of AIDS cohorts were measured as indicators for association with HIV-1 infection and with the rate of progression to AIDS. STRs are typically (but not always) located outside the coding region of functional genes. Because they are abundant (over 100,000 in the human genome) and nearly randomly Analyses of HIV-1-infected (n ϭ 420) seroconverters and antibody-negative individuals (n ϭ 90) were performed for Caucasian Americans (P values of allele frequency differences are shown). AIDS progression tests were performed for 410 Caucasian seroconverters for the AIDS-1993 (14) outcome by Cox analyses (15, 16) . Homozygotes and heterozygotes were analyzed separately for alleles with frequencies Ͼ0.25 and were combined when the frequencies were Ͼ0.03 by stepwise relative hazard regression. STR allele names reflect the molecular size in nucleotide base pairs of the allelic PCR segment. When P values were corrected (17) by the number of tests performed at that locus for AIDS-1993, IL10 was PЈ ϭ 0.02, whereas CCR2͞5 PЈ ϭ 0.20 and PЈ ϭ 0.005. A step-down Holm-Sidak correction (17) (18) (19) for the 19 loci as a family of tests produced significant association of CCR2͞5-linked STRs (PЈ ϭ 0.016) and IL10ϪR(Ϫ3975) (PЈ ϭ 0.054). A full version of this table, contingency tables of the infection tests, and full results of Cox analyses for progression tests are listed at http:͞͞lgd.nci.nih.gov. *IL10, CCR2͞CCR5, and STRL33 were analyzed with IL10Ϫ3975-R, IL10Ϫ1140-G, AFMB362WB9, GAAT12D11, and D3S2354, respectively. distributed, they are frequently informative in linkage mapping and population association studies (20) (21) (22) . The STR association approach is based on the presumption that genetic associations of AIDS outcomes with STR alleles͞genotypes mark mutational variants in adjacent functional genes that are carried on nonrandom haplotypes defined by linkage disequilibrium with STR alleles (23) (24) (25) (26) . STR genotype frequencies of HIV-1-infected patients were compared to those with documented high HIV-1 exposure who had not become infected. In addition, all prospective recessive and dominant STR genotypes were tested for association with differential rates of progression to AIDS by using a Cox proportional hazards model (15, 16) . *Genotypes from the STR loci were tested for infection and progression to AIDS considering each locus as a family of tests. The P values for STR IL10-R(Ϫ3975) were significant after Bonferroni correction for the number of alleles at each of these STR loci. Significant associations indicated by boldface were observed for HIV-1 infection (STRϪ1140-G) and for progression to AIDS. The association of the STR IL10-R(Ϫ3975) with disease progression is the result of a strong linkage disequilibrium between IL10-R(Ϫ3975) allele 283 ( Fig. 2 A) and the IL10-5ЈA promoter allele. Thus, a haplotype survey of 1,698 human chromosomes (Caucasian), which excluded ambiguous double heterozygotes, showed that 94% of IL10-5ЈA-bearing chromosomes carry an IL10-R(Ϫ3975)283 allele, a significant departure from random expectation for association of included alleles in that haplotype (68%; P Ͻ 0.0001). To determine whether AIDS protection was determined by recessive protection of IL10Ϫ1082-G or by the dominant susceptible influence of IL10Ϫ592-5ЈA, we compared three haplotype groups in Cox relative hazard model analyses: (i) those who retained one or two copies of IL10Ϫ592-5ЈA (ii) those who were homozygous for IL10Ϫ1082-G; and (iii) other patients who contained neither IL10Ϫ592-5ЈA nor IL10Ϫ1082G͞G genotypes (referent group). The significant epidemiologic signals were observed with the IL10Ϫ592-5ЈA-bearing genotypes (group i; RH ϭ 1.22-1.48, P ϭ 0.24 -0.01), but not with the IL10Ϫ1082-G͞G homozygotes who lack IL10Ϫ592-5ЈA (group ii; RH ϭ 0.66 -0.92, P ϭ 0.71-0.07) when compared to the referent group. The above three-haplotype-stratified analysis is similar to those used in very complex haplotype analyses (46) but much simpler and implicates IL10Ϫ592-5ЈA as the operative SNP in the epidemiologic effects on AIDS progression. ¶ The failure to reveal an infection effect of IL10-5ЈA in the face of association with a smaller group of rigorously defined (47) high-risk exposed uninfected patients (n ϭ 72; see text), could be because of the difficulty of assessing the extent of HIV-1 exposure in the larger group of HIV-1 antibody negative study participants (n ϭ 631 in this table).
Materials and Methods
with the IL10-5ЈA-bearing genotypes might reflect differences in survival because of better treatments late in the epidemic is unlikely, because clinical data used here were collected from 1978 to 1996, before wide use of highly active antiretroviral therapy (HAART). DNAs were extracted from immortal lymphoblastoid B cell lines established for each patient.
Genotype Assessment. A screen for new polymorphisms within the five coding exons of IL10 was undertaken by dHPLC and sequence analysis (36) of 45 Caucasians and 45 African Americans.
No additional coding single nucleotide polymorphisms (SNPs) were detected in the screens. Primers for SNP polymorphisms were: IL10-SNPϪ592 site (311 base pairs), IL10-SNPϪ592-A: 5Ј-TACTCTTACCCACTTCCCCC-3Ј and IL10-SNPϪ592-Z: 5Ј-TGAGAAATAATTGGGTCCCC-3Ј; IL10-SNPϪ1082 site (193 base pairs), IL10-SNPϪ1082-A: 5Ј-CACTACTAAG-GCTCCTTTGGG-3Ј and IL10-SNPϪ1082-Z: 5Ј-CCTGGAT-TAAATTGGCCTT-3Ј. Primers for STR polymorphisms were: IL10-G site, IL10-G-A: 5Ј-CAACCCAACTGGCTCCC-3Ј and IL10-G-Z: 5Ј-ATGGAGGCTGGATAGGAGGT-3Ј; and IL10-R site, IL10-R-A: 5Ј-CCCTCCAAAATCTATTTG-CATA-3Ј and IL10-R-Z: 5Ј-CTCATCAAGAAGCCCAAA-GC-3Ј.
Electrophoretic Mobility-Shift Assay. Nuclear extracts were prepared as described previously (37) .
Single-stranded oligonucleotides were commercially synthesized (Life Technologies, Rockville, MD) to span Ϫ604 to Ϫ581 of the IL-10 promoter as follows: 5Ј-GACCCCGCCTGTCCT-GTAGGAAGC-3Ј (IL10-5ЈC); and 5Ј-GACCCCGCCTG-TACTGTAGGAAGC-3Ј (IL10-5ЈA). The SP-1-binding site in HIV-1 LTR was GGGAGGCGTGGCCTGGGCGGACT-GGGGAGTGGCGA. Detailed methods are available at lgd. nci.nih.gov.
Results and Discussion
Candidate Gene Screening with STRs. One STR, IL10-G(Ϫ1140), a CA repeat 1 kb upstream of the IL10 gene (Fig. 1) , showed a weak association with sensitivity to HIV-1 infection (P ϭ 0.03, 10 df for 11 allele locus), whereas all other loci showed no significant associations with infection (Table 1) ; a summary of IL10-linked STR association with HIV-1 infection is in Table 2 . For disease progression rate association tests, four loci revealed significant associations (IL10-RϪ3975, P ϭ 0.003; and three STRs within 1 cM of CCR5 and CCR2, ref. 18, AFMB362WB9, P ϭ 0.05; GAAT12D11, P ϭ 0.0009; and STRL-33, P ϭ 0.05). On correction for multiple tests (17-19, 48, 49) , IL10-RϪ3975 and GAAT12D1 retained statistical significance (Table 1) . A survival analysis illustrating the association of IL10-R(Ϫ3975)-283͞283 homozygosity with relatively rapid progression to AIDS is presented in Fig. 2 
A.
The observed infection and disease progression association with STRs tightly linked to CCR5 (Table 1) was not unexpected given previously described CCR5-⌬32 genetic restriction on HIV-1 infection and progression plus the strong linkage disequilibrium of the two adjacent STRs, AFMB362wB9 and GATT12D11 (4, 12, 50) , but an IL10 effect was not anticipated. The IL10-associated signal with linked STRs for both HIV-1 infection and the rate of AIDS progression among infected patients (Table 1 ; Fig. 2 A) was studied further by screening for new and previously identified SNPs within the coding exons and promoter region (42, 38, 51) of the IL10 gene (Fig. 1 A) .
IL10 SNPs.
No variants were observed in a dHPLC and sequencing screen of 90 individuals across five exons ( Fig. 1 A) ; however, three single nucleotide variants were detected within the upstream promoter region: an A-G transition at position Ϫ1082, a C-T transition at position Ϫ819, and a C-A transversion of position Ϫ592 measured from the transcription start site (designated IL10-5ЈϪ592A and abbreviated IL10-5ЈA; Fig. 1A ). Because sites Ϫ819 and Ϫ592 were found to occur in complete linkage disequilibrium association with each other (see also refs. 42, 43), we genotyped two IL10 promoter SNP variants, positions Ϫ592 (tracking Ϫ819) and Ϫ1082, for association with HIV-1 infection or disease progression. These two variants were particularly interesting, because several previous reports have demonstrated quantitative difference in IL10 transcription and͞or expression determined by alternative alleles in stimulated peripheral blood mononuclear cells (42, 44, 45, 51) . The less common variants at both SNP sites showed significant associa- tions with one or more AIDS outcomes by using four endpoint AIDS definitions (14, 35) (Table 2 ). Alleles at the four loci (two STRs and two SNPs, each within 4,000 base pairs on chromosome 1q31-32) were also found to be in strong linkage disequilibrium with each other, and haplotype analysis narrowed the focus of the genetic epidemiological association signal to the SNP allele at position Ϫ592, termed IL10-5ЈA (Table 2 
legend).
The IL10-5A Variant Accelerates Progression to AIDS in Late Infection.
The allele frequencies of IL10-5ЈA in four ethnic groups were as follows: Caucasians, 0.236 (n ϭ 2,208 study participants); African Americans, 0.400 (n ϭ 937); Hispanics, 0.327 (n ϭ 153); and Asians, 0.600 (n ϭ 47). Allele frequencies of the most common or wild-type allele (IL10-5ЈϪ592C, abbreviated IL10-ϩ here) is equal to 1 minus the IL10-5ЈA frequencies for each ethnic group. An influence of the IL10-5ЈA on HIV-1 infection was seen in a categorical analysis of allele and genotype frequency distributions among 377 HIV-1-infected seroconverter patients plus a group of 72 high-risk exposed uninfected (HREU) individuals (those with extremely high-risk sexual practices) (12, 13, 47) but was not seen in a comparison to a collection of all uninfected individuals (Table 2) . (We selected the well-characterized Multicenter AIDS Cohort Study seroconverters to avoid the previously described frailty bias of certain cohorts and of seroprevalents that are nonrandomly depleted of very rapid progressors to AIDS) (32, 33) . A diminution in IL10-5ЈA alleles (P ϭ 0.04) and IL10-5ЈA-bearing genotypes in HREU (31.0% among HREU individuals compared to 45.1% among infected patients; odds ratio ϭ 1.75; Fisher's exact test, P ϭ 0.03), suggested that the IL10-5ЈA allele was associated with increased risk for HIV-1 infection.
A role for IL10-5ЈA in disease progression among 769 HIV-1-infected seroconverters was demonstrated by survival analyses by using the Cox proportional hazards model (15, 16) (Fig. 2 Table 3 ). For combined and individual cohort analyses, heterozygous IL10-ϩ͞5ЈA and homozygous IL10-5ЈA͞5ЈA patients were indistinguishable in the rates of progression to 4 AIDS end points (Fig. 2B) . However, a highly significant acceleration to AIDS progression was apparent among HIV-infected Caucasians of genotypes IL10-5ЈA͞5ЈA or IL10-ϩ͞5ЈA compared to IL10-ϩ͞ϩ homozygotes for every AIDS outcome (P ϭ 0.0009-0.05, Table 3 ). This susceptible effect was also apparent when the protective effects of other AIDS restriction alleles, CCR2-64I and CCR5-⌬32, were considered as covariables in adjusted Cox analyses (Table 3) .
B-D;
The patterns of AIDS acceleration illustrated in Fig. 2 B-D suggest a greater survival difference in IL10-5ЈA-bearing genotypes in later, as compared to earlier, stages of HIV-1 infection. A formal analysis of time dependence in Table 3 applies a relative hazards model partitioned into early progressors (0-5 years after seroconversion) and late͞slow progressors (Ն5 years after seroconversion). A partitioned time interval approach with combined and separate cohorts is also presented. These analyses show that acceleration to AIDS associated with IL10-5ЈA-bearing genotypes was more pronounced starting approximately 5 years after HIV-1 exposure, whereas the IL10-5ЈA allele has no significant effect on AIDS progression in the initial 5 years after infection.
The tendency of IL10-5ЈA-bearing genotypes to progress to AIDS rapidly was also apparent in a defined disease category analysis (Fig. 3) , which allows the addition of seroprevalent patients (those who enter the cohorts already HIV-1 positive) to the slow͞nonprogressor category, because avoiding AIDS for longer Statistical analysis. Cox models (15, 16) were used for calculating relative hazards and P values for separate and combined cohorts and racial groups, as we have previously reported (5, 6) . Nonsignificant 2-and 3-year windows in the initial infection period were grouped together and later times considered separately in further Cox analyses of AIDS outcomes (14, 35) . A strict and conservative Bonferroni correction of the 120 P values presented would mean that only those of P Յ 0.00042 are significant, which is coincidentally equivalent to the smallest observed P value (P ϭ 0.0005; Multicenter AIDS Cohort Study, AIDS-1993 Ͼ5-year portion of the analysis). Because the tests were not independent, the observed statistical associations seem robust. Eighteen of the AIDS progression P values are lower than 0.002 (some by an order of magnitude), and overall, 45 are P Յ 0.05 and 30 are P Յ 0.01. *Time was not taken into account in all models and was included as an interaction term by separating 0 -5 and Ͼ5 years in the models (except death, where 0 -6 and Ͼ6 years was used). † Relative hazards were shown as RHu from unadjusted models and as adjRH from adjusted models, in which the effects of the previously described CCR5-⌬32 and CCR2-64I genotypes were taken into account. The effects of IL10 and CCR (CCR5-⌬32 and CCR2-64I) appear additive, because, in the Cox analyses, interaction terms were not significant (P ϭ 0.53-0.87) for the four outcomes in Caucasians. ‡ IL10-5ЈA AIDS accelerating effects were most apparent in Caucasian and mixed ethnic group analyses. The less significant P values in African Americans are likely a consequence of fewer patients (n ϭ 220 seroconverters), fewer AIDS cases after 5 years of infection (15 AIDS-1987 and 5 AIDS deaths), and the relative recency of the recruitment of the AIDS Link to the Intravenous Experience cohort, which comprises 70% of the African American seroconverters (5, 27) . This interpretation is supported by high relative hazards (at Ͼ5 years); RH ϭ 3.41 and 1.93 for CD4 Ͻ 200 and AIDS-1993, respectively, the two earliest AIDS end points.
periods (i.e., Ͼ10 years) is informative whether the interval of infection is precise or is greater than the time period since enrollment (4) (5) (6) (7) (8) . The frequency of AIDS acceleration genotype IL10-5ЈA͞5ЈA or IL10-ϩ͞5ЈA was considerably higher than IL10-ϩ͞ϩ in patients who progress to AIDS 0-10 years after seroconversion vs. those who avoid AIDS for 10 or more years (Caucasian P ϭ 0.0007-0.05). Replication of this effect is also apparent when different risk groups (hemophiliac, homosexual) or different ethnic categories (Caucasian American, African American) are examined separately (Fig. 3) . The frequency of the dominant AIDSaccelerating IL10-5ЈA allele is common (frequency, 0.23-0.6 in various ethnic groups; see above), and 25-30% of patients who avoid AIDS for 10 years or longer do so as a consequence of their IL10-ϩ͞ϩ genetic protection (attributable risk computation; refs. 52, 53) . The results of both the survival (Table 3 ) and defined disease category analyses (Fig. 3) affirm a strong dominant IL10-5ЈA association with more rapid progression to different AIDS outcomes, particularly in the later stages of HIV-1 infection. 5A, CCR5-⌬32, and CCR2-64l in HIV-1͞AIDS . The AIDSaccelerating effects for IL10-5ЈA were compared to the protective effects of CCR5-⌬32 and CCR2-64I in delaying AIDS (4, 5, 10, 12, 13) . Because the protective effects of CCR2-64I and CCR5-⌬32 are dominant, genetically independent, and equivalent in their influence on AIDS progression (5), we combined CCR5 and CCR2 protective genotypes (CCR5-ϩ͞⌬32, CCR2-ϩ͞64I, and CCR264I͞64I) and examined survival analyses of patients in combined cohorts for IL10-5ЈA acceleration of AIDS and for CCR2͞5 protection (Fig. 2 E and F) . Separations of genotype-specific survival curves are gradual, and the strength of the IL10-5ЈA effects is equivalent to (if not slightly greater than) but in opposite directions of the CCR2͞5 effects (compare Figs. 2 C and D to 1; ref.  5 ). Perhaps more illuminating is the analysis of CCR5, CCR2, and IL10 genotypes together (Fig. 2 E and F) where patients protected by CCR5-⌬32 or CCR2-64I with the IL10-ϩ͞ϩ (also protective) genotype avoid AIDS considerably longer than do CCR5-⌬32 or CCR2-64I protected patients carrying the IL10-5ЈA accelerating genotypes (red vs. green lines: relative hazard (RH) ϭ 0.62, P ϭ 0.02; RH ϭ 0.65, P ϭ 0.05 for AIDS-1993 and AIDS-1987, respectively). Similarly, IL10-5ЈA-accelerating genotypes carrying wild-type (susceptible) CCR2-ϩ and CCR5-ϩ alleles (black lines, Fig. 2 E and F) progress more rapidly than any genotypic group including IL10-ϩ͞ϩ plus CCR5-ϩ or CCR2-ϩ (i.e., CCR2͞5 susceptible) genotypes (black vs. blue lines: RH ϭ 1.38, P ϭ 0.02; RH ϭ 1.47, P ϭ 0.01 for AIDS-1993 and AIDS-1987, respectively). These patterns demonstrate the cumulative effects in cohort populations of these genetic influences.
IL10-
IL10-5A Mediates Differential Nuclear-Binding Activity. The DNA sequence surrounding the IL10-5ЈA variant (positions Ϫ604 to Ϫ581) was examined for homology to recognized binding sites for known transcription factors (41) and was shown to include motifs specific for SP-1 and avian erythroblastosis virus (ETS) familybinding sites (Fig. 1 A) . The IL10-ϩ sequence lacks the ETS motif, whereas the IL10-5ЈA retains it, posing a potential molecular mechanism for increased IL10 production in peripheral blood mononuclear cells of IL10-ϩ͞ϩ homozygotes compared to IL10-5ЈA͞5ЈA homozygotes (51) . To resolve potential allele distinctions in vitro, DNA sequence oligonucleotides representing IL10-ϩ and IL10-5ЈA (Ϫ604 to Ϫ581, approximately 11 base pairs on either side of SNP-592) were synthesized and tested for specific DNA-binding protein recognition by using the electrophoretic mobility-shift assay with nuclear extracts from phytohemagglutinin-stimulated primary human peripheral blood T lymphocytes (37) . Two specific binding complexes were resolved by using IL10-ϩ-specific oligonucleotides, but only one of these bound to IL10-5ЈA-specific oligonucleotides (Fig. 1B) . Specificity for the binding was demonstrated by the fact that competitive binding of cold (100-fold excess) allele-specific oligonucleotides eliminated complex formation completely. Cold synthetic SP-1 oligonucleotide effectively competed with and eliminated the faster migrating complex, implicating SP-1 as binding both IL10 promoter alleles. A synthetic oligonucleotide designed from the ETS core consensus sequence (41) did not compete for either complex formation, indicating that nuclear proteins other than ETS family members may be involved in the formation of the IL10-ϩ-binding complex. (Table 1) . IL10-R(Ϫ3975)Ϫ283͞283 homozygotes are associated with relatively rapid progression to AIDS after infection with HIV-1 (Fig. 2 A) , and this STR allele, IL10-R(Ϫ3975)Ϫ283, is tracking an IL10 promoter SNP allele (IL10-5ЈA) by strong positive linkage disequilibrium in human popula- tions. IL10-5ЈA-bearing individuals (IL10-5ЈA͞5ЈA or ϩ͞5ЈA) also progress much more rapidly to AIDS end points than patients homozygous for the more common wild-type allele (IL10-ϩ͞ϩ) (Fig. 2 C-F; Table 3 ). IL10-5ЈA may also enhance HIV-1 infection insofar as the frequency of IL10-5ЈA alleles and genotypes is greater among infected individuals than among high-risk exposed uninfected patients. The facilitation of HIV-1 disease progression by IL10-5ЈA is consistent with the possibility that differential promoter allele affinity for transcription factors (such as ETS, which is present in IL10-5ЈA but not in IL10-ϩ) (Fig. 1B) plays a role in diminished transcription and IL10 production observed for IL10-5ЈA (44, 51) . Decreased IL10 could contribute to accelerating HIV-1 replication and the appearance of late-stage X4 or T-tropic HIV-1 strains, a scenario consistent with more pronounced AIDS acceleration effects in later stages (Ͼ5 years) of infection (Table 3) .
In addition to demonstrated inhibitory activity on macrophage growth and on cytokine secretion from T-helper cells (54, 55) , IL10 also inhibits HIV-1 replication in macrophages (56, 57) , and serum IL10 concentrations are elevated in AIDS patients, particularly in later stages of disease (58) . High levels of IL10 were detected among AIDS patients with non-Hodgkin's Blymphoma compared to HIV-1-infected individuals without lymphoma (59) . Studies showing that elevated IL10 mRNA is seen in slower progressors to AIDS (60) plus the knowledge that IL10 inhibits macrophage and HIV-1 proliferation (56, 57) all suggest that it can stem HIV-1 spread, possibly by limiting activated macrophages available for HIV-1 replication. This interpretation gains support from the observation that HIV-1-infected patients with declining CD4 cell counts also show a decline in IL10 production by peripheral blood cells (61) . The data reported here suggest that the IL10-5ЈA promoter allele, which is associated with diminished IL10 production (44, 51) and failure to bind a putative nuclear transcription factor (Fig. 1B) , can accelerate AIDS progression likely through facilitation of viral replication in infected patients. AIDS acceleration mediated by an IL10-5ЈA promoter variant offers support for targeted immunotherapeutic strategies that would retard the deadly progression to AIDS by mimicking or enhancing the natural inhibitory role of the IL10 cytokine.
